Does Tirzepatide Cause Hair Loss? (Mounjaro & Zepbound Explained)

What Is Telogen Effluvium and Why Does Weight Loss Trigger It?

To understand why tirzepatide users report hair shedding, you need to know how hair actually grows. Each follicle cycles independently through three phases: anagen (active growth), catagen (transition), and telogen (rest and shedding). Under normal conditions, about 85-90% of your follicles are in anagen at any given time, producing a continuous supply of new hairs that keeps shedding manageable at 50-100 strands per day.

When the body experiences a significant physiological stressor, a large cohort of follicles exits anagen simultaneously and enters telogen. Roughly three months later, all those follicles shed at once, producing the characteristic diffuse thinning of telogen effluvium. The trigger can be surgery, illness, childbirth, or rapid, significant weight loss. Tirzepatide, which produced 20.9% mean body weight loss at 72 weeks on the 15mg dose in the SURMOUNT-1 trial, is a potent weight-loss driver and therefore a potent telogen effluvium trigger.

The 2024 JAAD case report by Gordon, Musleh, and Bordone put it plainly: "Although some reports link GLP-1 agonists to hair loss, this effect appears temporary and due to telogen effluvium secondary to weight loss." That framing is important: the shedding is mediated by the weight loss, not by the drug's direct action on follicle biology.

The Hair Growth Cycle in Brief

• Anagen (growth phase): lasts 2-7 years per follicle; the hair shaft actively grows.
• Catagen (transition): lasts about 2 weeks; follicle shrinks and detaches from blood supply.
• Telogen (resting/shedding): lasts about 3 months; old hair sits in place, then falls out as new anagen growth pushes it out.

Normal daily shedding: 50-100 hairs. During telogen effluvium, shedding can reach 200-300+ hairs per day, which is alarming but not medically dangerous in the context of a healthy follicle base.

Why Rapid Weight Loss Is the Trigger, Not the Medication

Tirzepatide produces substantial, sustained weight loss, and that weight loss is what stresses follicles. Tirzepatide works as a dual agonist targeting GLP-1 and GIP receptors, driving appetite suppression and caloric reduction. In SURMOUNT-1, participants on 15mg lost an average of 20.9% of body weight over 72 weeks. That degree of weight loss creates a physiological stress state similar to what occurs after major surgery or severe illness.

Nutritional deficits compound the follicle stress. When caloric intake drops sharply, protein and micronutrient availability for "non-essential" structures like hair follicles falls. The body deprioritizes hair growth in favor of vital organs. The 2026 systematic review by Gupta and colleagues confirmed that "rapid weight loss emerged as a potential contributor, particularly for telogen effluvium," and noted dose-dependency and higher incidence signals for both semaglutide and tirzepatide compared to other GLP-1 class agents. The tirzepatide molecule itself does not damage follicles directly.

What Does the Clinical Evidence Say About Tirzepatide Hair Loss?

The evidence base for tirzepatide hair loss has strengthened considerably in 2026. Three peer-reviewed studies now provide population-level confirmation of the association, while the mechanism literature anchors it to weight-loss-mediated telogen effluvium rather than direct follicle toxicity.

SURMOUNT-1 Trial Context

SURMOUNT-1 (Jastreboff et al., NEJM, July 2022) enrolled 2,539 adults and ran for 72 weeks. The 15mg tirzepatide arm produced 20.9% mean body weight loss, with 57% of participants losing at least 20% of body weight. The published NEJM paper reported the gastrointestinal event profile common to GLP-1 class agents rather than breaking out hair loss, which later surfaced as a quantified row in the Zepbound prescribing information. The trial's headline finding matters here for a different reason: the magnitude and speed of the weight loss it produced is precisely the physiological context that makes telogen effluvium likely in a subset of users.

2026 Population Cohort Findings

Three 2026 studies collectively build the case:

• Herrera and Bordeaux, JAAD (2026): A retrospective TriNetX cohort analysis confirmed an association between tirzepatide and semaglutide use and new-onset hair loss at the population scale. This is the strongest study design available outside a randomized controlled trial for this outcome, and its publication in the Journal of the American Academy of Dermatology gives it significant clinical weight.
• Argobi et al., J Cosmet Dermatol (2026): A cross-sectional analysis of 254 GLP-1 users found that severe hair loss was more common in Mounjaro users (43.4%), with an adjusted odds ratio of 3.02 versus the reference group (p = 0.009). Limitations: cross-sectional design, self-reported outcomes, and 254 participants. This figure should not be read as a population incidence rate; it reflects the proportion of GLP-1 users who already had hair loss and reported it as severe.
• Gupta et al., Sci Prog (2026): A systematic review of GLP-1 therapies and hair loss found that semaglutide and tirzepatide "demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies" among the class. The review identified females as disproportionately affected and noted a dose-dependency pattern, consistent with tirzepatide's weight-loss dose-dependency.

The pattern across these three studies is consistent: tirzepatide-associated hair shedding is real at population scale, it tracks with the drug's weight-loss efficacy, and no study to date finds direct follicle toxicity from tirzepatide itself.

Who Is Most at Risk of Hair Loss on Tirzepatide?

Not everyone who loses weight on tirzepatide will experience noticeable hair shedding. Several factors appear to raise the risk, and understanding them can help you monitor and intervene early.

• Faster rate of weight loss: The more rapid the weight change, the more follicles enter telogen simultaneously. Higher tirzepatide doses drive faster loss and may carry higher risk.
• Lower protein intake: Caloric restriction that cuts into protein intake deprives follicles of the amino acid building blocks they need, amplifying the stress signal.
• Female sex: The Gupta et al. 2026 systematic review found that "females appeared to be disproportionately affected." This is consistent with the known greater prevalence of telogen effluvium and nutritional deficiency-related hair loss in women.
• Pre-existing micronutrient deficiencies: Low ferritin (stored iron) is an independent risk factor for telogen effluvium even without rapid weight loss. Starting tirzepatide with low ferritin, zinc, or vitamin D compounds the follicle stress.
• Extended duration of rapid weight loss: Shedding may persist or cycle if rapid weight loss continues for 6-12 months, consistent with longer GLP-1 use as a predictor in the Argobi et al. 2026 cross-sectional analysis.

Is This More Likely on Mounjaro or Zepbound?

Mounjaro and Zepbound contain the identical active ingredient, tirzepatide, at the same doses and titration schedule. The indication differs: Mounjaro is approved for type 2 diabetes management, Zepbound for obesity and weight management. Because people on Zepbound are typically titrating toward higher doses specifically to sustain weight loss, the overall weight-change magnitude over time may be similar or slightly higher in the obesity indication. The practical risk of telogen effluvium should be considered equivalent between both brands. The Argobi et al. 2026 study enrolled patients using the Mounjaro brand specifically, but the mechanism is not brand-specific.

How to Prevent or Reduce Hair Loss While on Tirzepatide

No single intervention eliminates telogen effluvium completely, but addressing the nutritional root drivers can meaningfully reduce severity. Talk to your doctor before starting any new supplementation.

Protein Intake

Adequate protein is the most important dietary factor for follicle support during a caloric deficit. Hair shafts are approximately 95% keratin, a protein. When protein intake falls too low, the body cuts allocation to non-vital structures like hair first. Tirzepatide's appetite suppression can make hitting daily protein targets feel effortful, but it is the thing most worth prioritizing. Your doctor or a registered dietitian can set a specific protein target based on your weight and health status. For broader context on nutrition during tirzepatide treatment, see the tirzepatide dosing guide.

Key Micronutrients to Monitor

Four micronutrients have meaningful evidence links to telogen effluvium risk:

• Iron / ferritin: Low serum ferritin is one of the strongest independent risk factors for telogen effluvium. A ferritin level under 30-50 ng/mL is commonly cited as a threshold where hair cycling is impaired. This is testable and correctable. Ask your provider to check ferritin specifically, not just hemoglobin.
• Zinc: Supports hair matrix cell proliferation. Deficiency is associated with hair thinning. Zinc can be included in a standard micronutrient panel.
• Vitamin D: Vitamin D receptors are present in hair follicles and have been associated with follicle cycling. Deficiency is common, especially in people with obesity.
• Biotin: Widely marketed for hair growth, but the evidence supports benefit mainly in people with confirmed biotin deficiency. Taking biotin without deficiency is unlikely to prevent telogen effluvium, though it carries low risk.

Avoid Extreme Caloric Restriction

Tirzepatide's appetite suppression is powerful, especially in the first weeks at a new dose. Some people inadvertently eat far below safe minimums because they feel no hunger at all. That extreme restriction amplifies follicle stress beyond what the weight loss alone would cause. Eating a minimum of 1,000-1,200 kcal per day (or whatever your doctor specifies) with adequate protein gives follicles a nutritional floor. If nausea is making eating difficult, see the tirzepatide side effects guide for GI management strategies.

Will Hair Grow Back After Tirzepatide Hair Loss?

For the vast majority of people, yes. Telogen effluvium is a temporary disruption to the hair cycle, not permanent follicle destruction. Once the physiological stressor, meaning rapid weight loss or severe caloric restriction, subsides or is managed, follicles return to anagen and begin producing new hair.

Recovery Timeline

Shedding typically peaks within the first several months of treatment when weight loss is most rapid, then gradually slows. Most cases resolve within 6-12 months. Full density recovery may take the entire 12 months, since anagen hair growth proceeds at roughly 1 cm per month and the full strand length takes time to reappear.

A useful pattern to watch: if shedding was severe at months 3-5 and you are now at month 7-8 with less daily loss, that is a reliable recovery signal even if density has not fully returned. The ZepBound side effects corpus documents this 6-12 month resolution window as the corpus-standard recovery range for tirzepatide users.

If shedding persists beyond 12 months, is patchy rather than diffuse across the scalp, or is accompanied by other symptoms (fatigue, cold intolerance, brittle nails), consult a dermatologist. These patterns may indicate androgenetic alopecia, thyroid dysfunction, or another cause that tirzepatide-related shedding may have unmasked or exacerbated, but did not create.

Do You Need to Stop Tirzepatide?

Most prescribers do not recommend stopping tirzepatide for hair shedding alone. The metabolic benefits are substantial, and the hair loss is driven by the weight loss itself, not the molecule. Stopping also does not immediately end shedding: the telogen effluvium cycle that was triggered continues through its roughly 3-month telogen phase regardless of whether the original stressor continues. The decision to pause or discontinue belongs with whoever prescribed it, not a solo call made at home.

Is Hair Loss Listed as a Side Effect in the Zepbound or Mounjaro Label?

Yes, for Zepbound. Hair loss is a labeled adverse reaction in the Zepbound prescribing information, and it is prominent enough to appear in the Highlights section among the reactions reported in at least 5% of patients. The Section 6.1 clinical trials table puts it at 5% on the 5 mg dose, 4% on 10 mg, and 5% on 15 mg, against 1% on placebo. The label also gives it a dedicated subsection noting the effect was associated with weight reduction and was far more common in women than men: 7.1% of female patients versus 0.5% of male patients, against 1.3% of women on placebo.

Mounjaro is different, and the distinction matters if you are searching the two labels. Mounjaro lists alopecia only under Section 6.2, post-marketing experience, in the skin and subcutaneous tissue category. It does not appear in Mounjaro's clinical trial adverse reaction table or in its Highlights list, where the most common reactions are the gastrointestinal ones: nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.

One terminology note that trips up label searches: the Zepbound label never uses the word "alopecia" at all. It says "Hair Loss". Searching either label for "alopecia" and finding nothing is easy to misread as the effect being unlabeled, when for Zepbound it is both labeled and quantified. The peer-reviewed cohort literature published in 2026 in JAAD and J Cosmet Dermatol, plus pharmacovigilance signals from a 2026 systematic review, characterize the same effect in more detail than the trial tables do.

Tirzepatide Hair Loss vs Semaglutide Hair Loss

Both tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) are associated with hair shedding through the same rapid-weight-loss mechanism. The 2026 systematic review by Gupta et al. found that both drugs "demonstrated the highest incidence rates of hair loss and more frequent signal detection in pharmacovigilance studies" compared to other GLP-1 receptor agonist agents. This makes sense: both are the most efficacious weight-loss drugs in the class.

Tirzepatide produced 20.9% average weight loss in SURMOUNT-1; semaglutide hit 14.9% in STEP 1. More weight loss means a stronger telogen effluvium trigger. No head-to-head trial has directly compared hair loss rates between the two drugs. For a full comparison, see the tirzepatide vs semaglutide guide. A companion article on semaglutide-specific hair loss is in preparation and will link here when published.

For general context on semaglutide side effects, see the semaglutide side effects guide.